12 Analysts Have This To Say About Ionis Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Ionis Pharmaceuticals (NASDAQ:IONS) has been analyzed by 12 analysts over the past three months, showing a range of perspectives from bullish to bearish. The average 12-month price target is $63.83, with a high of $82.00 and a low of $53.00. Recent ratings include several 'Buy' and 'Outperform' recommendations, with some analysts raising their price targets.
August 02, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals has received mixed analyst ratings over the past three months, with an average 12-month price target of $63.83. Recent ratings include several 'Buy' and 'Outperform' recommendations, indicating a generally positive outlook.
The majority of analysts have given 'Buy' or 'Outperform' ratings, and the average price target has increased to $63.83. This suggests a generally positive outlook for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100